The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

ESMO Congress 2024: ESMO-CDDF Educational Session

Regulatory Challenges in Clinical Cancer Drug Development

16 September 2024, 08:30-10:00 CET

CC5 – Zaragoza Auditorium, Barcelona, ES

 

The CDDF and ESMO will hold a joint session on “Regulatory Challenges in Clinical Cancer Drug Development” on Monday 16 September from 8:30 to 10:00 AM (CET) at CC5 – Zaragoza Auditorium during the ESMO Congress 2024 in Barcelona, Spain.
SESSION CHAIRS
  • Ruth Plummer (CDDF & Newcastle University, UK)
  • Teresa M. Amaral (Tübingen, Germany)

AGENDA: (CET time zone)
08:30 – 08:50    Specifics of CHMP assessment of cancer drugs – Aaron E. Sosa Mejia (Danish Medicines Agency)
08:50 – 09:10    Current status and implications of the In Vitro Diagnostics regulation – Audrey Wolf (EFPIA, BE)
09:10 – 09:30    Initiatives for a joint EU HTA assessment – Marcus Guardian (Dierks+Company, BE)
09:30 – 10:00    Q&A and discussion

Cancer Drug Development Forum asbl
Registered office: c/o BLSI, Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium
Register of legal entities: the French Speaking Enterprise Court in Brussels
Enterprise number: 738.523.752

info@cddf.org
Tel: +32 2 880 62 70